When administered intratumorally to in vivo syngeneic mouse tumor models of injectable indications that may be clinically amenable to surgical resection (melanoma, hepatocellular carcinoma, colon carcinoma), mPH-762 treatment provided enhanced tumor control correlating with dose; degree of response correlated with overall known response of each model to systemic PD-1 inhibition. The gene discussed is PDCD1; the disease is melanoma.